Powderbum, they aren't skeptical about the calmare technology or whether the clinical trials are going to come out successful, but consider every action that Johnson and the board has taken in the last year or so and you can't honestly say it's been the ideal moves for selling a lot of calmare machines or in the best interests of the shareholders. There is very little transparency, and a lot of discontent with what they are doing and the mere fact that johnson is getting paid 25k a month+stock options makes anyone who cares about this upset with the BOD in how they are drowning this company.
Why would the BOD appoint a man who was last CEO of a company that went bankrupt with no experience in biotechnology, or anything remotely related?
Market Data 
Markets 
AI
